Register for Virtual HPAPI Technical Symposium – June 2, 2022

Next generation manufacturing of the most potent compounds in pharma

June 2, 2022

10:30 AM – 1:30 PM EDT | 4:30 PM – 7:30 PM CEST

ADCs and other targeted therapies are opening up a world of exciting opportunities to

change the nature of cancer treatment. HPAPIs are a critical element of these therapies.

Innovators are seeking to bring new treatments to market faster, more efficiently and without compromise to safety.

Register today and learn about

• Planning and implementation for high potency API manufacturing
• Containment strategy for safe single-digit nanogram OEL handling
• Novel payloads requiring improved handling capabilities
• Latest trends in HPAPI drug development

In addition to the symposium, we will showcase our brand new, state-of-the-art CDMO facility, which includes 6 new best-in-class kilo scale production suites for single-digit nanogram containment handling and greatly expanded quality control labs for analytical testing.

AGENDA:

Opening: Dirk T. Lange, EVP, Head of Life Science Services, Merck KGaA, Darmstadt, Germany

Chair: Matt Hanson, Commercial Head of Synthesis and ADC CM, Merck KGaA, Darmstadt, Germany

Presentations:

• Requirements to ensure an integrated SHE control strategy, Hugh Tole, Head – Group Occupational Hygiene, Roche
• Design & construction of the new HPAPI facility in Verona (WI), Hani El Kassas, Program Manager, Merck KGaA, Darmstadt, Germany
• Process development of a Tubulysin drug-linker, Alan Jin, Principal Scientist, Chemical Process and Analytical Development, SeaGen
• PBDCore™ expands broad payload product line to simplify ADC payload development, James Walker, Associate Director Process Chemistry API R&D, Merck KGaA, Darmstadt, Germany

Tour:  Ahmed Yusuf, Manufacturing Manager Verona (WI), Merck KGaA, Darmstadt, Germany

More details of the webcast, abstracts and speaker can be found on the registration page.